... One Dose of Lead Asset, INT230-6 in Phase 2 INVINCIBLE Neoadjuvant Breast Cancer Study at the San Antonio Breast Cancer Symposium (SABCS) ...
News
- Intensity Therapeutics' Reports Up to 100% Tumor Necrosis After One Dose of Lead Asset ...
- Dantari emerges with a new way to make cancer drug conjugates - BioPharma Dive
Dive Brief // Emerging biotech ... set to be presented Thursday at the San Antonio Breast Cancer Symposium, ... STORYLINE // Emerging biotech.
- Longer follow-up supports benefit of abemaciclib for high-risk breast cancer - Healio
SAN ANTONIO — The benefit of adding abemaciclib to adjuvant endocrine therapy for certain patients with high-risk breast cancer deepened with time ...
- Metastasis 'Doorway' May Lead to Racial Disparities in Breast Cancer | MedPage Today
SAN ANTONIO -- Black patients with certain types of breast cancer treated with chemotherapy had increased concentrations of a cellular complex ...
- Kisqali Outperforms Combination Chemo in Aggressive HR-Positive, HER2-Negative Breast Cancer
SAN ANTONIO – A Phase II trial of Novartis' CDK4/6 inhibitor Kisqali (ribociclib) plus endocrine therapy showed improvement in progression-free ...